Recently, it has been reported that the inhibition of sodium-glucose cotransporter 2, which is useful for treating diabetes and CKD, reduces SA-βGal activity in visceral adipose tissue and attenuates pathological aging [46]. The gene discussed is SLC5A2; the disease is diabetes mellitus.